Bifurcation Lesion Analysis and STenting / BLAST (BLAST)

June 14, 2024 updated by: Volcano Corporation
The purpose of this research study is to determine if Intravascular Ultrasound (IVUS) grayscale and VH (Virtual Histology)-IVUS pre-stenting can assess more accurately the location, amount, and type of a blockage than angiogram alone. Additionally, this study is to determine if IVUS grayscale and VH-IVUS guidance will result in improved acute and long term procedural outcome vs. bifurcation stenting with only angiographic guidance in native coronary arteries.

Study Overview

Detailed Description

Global multi-center, prospective, two-arm, randomized study. Patients will be randomized to either blinded or non-blinded IVUS assessment before the treatment of coronary bifurcation lesions. Treatment will be based either on grayscale and VH IVUS versus angiography alone.

After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure; the non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure. In all patients, both pre- and post intervention, IVUS grayscale and VH-IVUS will be preformed on both branches of the bifurcation (blinded or non-blinded).

Study Type

Observational

Enrollment (Actual)

195

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus, Denmark
        • Kardiologisk laboratorium/B-lab Skejby Sygehus
      • Bordeaux, France
        • Clinique Saint Augustin
      • Brest, France
        • Hopital de la Cavale Blanche-CHU
      • Nantes, France
        • Nouvelles Cliniques Nantaises
      • Torino, Italy
        • Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista al Torino Departp Emodinamica Universitaria
      • Riga, Latvia
        • Pauls Stradins Clinical University Hospital
      • Enschede, Netherlands
        • Medisch Spectrum Twente
      • Warsaw, Poland
        • CSK MSWiA w Warszawie
      • London, United Kingdom
        • St. Thomas Hospital Cardiothoracic Centre
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Saint Luke's Hospital-Mid America Heart Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Per Protocol Population All patients who met all inclusion/exclusion criteria, completed the study intervention procedure as described in the protocol, and completed the 1-month follow-up.

Intent to Treat Any subject randomized into the trial and there was an attempt to use the IVUS but either side branch was not IVUS'd pre and post intervention.

Description

Inclusion Criteria:

  1. Patient must be greater than 18 years of age.
  2. Patient is scheduled for coronary stenting of a bifurcation lesion in a native artery using Drug Eluting Stents (DES).
  3. Patient must be willing and able to read and sign the informed consent document before planned coronary intervention.
  4. If the patient is female and of child bearing potential, a pregnancy test (serum HcG or urine dip stick) is negative within 7 days of the procedure.
  5. Side branch lumen diameter min of >2 mm by visual, angiographic estimate.
  6. Patient must agree to be available for follow-up at 30 days, 1 and 2 years after procedure.
  7. Other significant lesions in different vessels should be treated successfully (residual stenosis < 30%, normal TIMI flow, no EKG modification) before treating the index bifurcation lesion.

    -

Exclusion Criteria:

  1. The patient experiences significant hepatic disease, renal disease, lung disease and/or malignant disease with unfavorable prognosis.
  2. Any contraindications for IVUS interrogation as determined by the investigator including sever vessel tortuosity and severe calcification by angiogram.
  3. Side branch lumen diameter < 2 mm by visual, angiographic estimate.
  4. The patient suffered a cerebrovascular accident within the past 6 months and has residual effects from the event.
  5. The patient suffered significant (as determined by the Investigator) gastrointestinal bleeding within the past 3 months.
  6. The most recent white blood cell count less than 3,000 cell/mm3 or the number of platelet is less than 100,000 cell/mm3.
  7. The patient has contraindication to antithrombotic regimen or anticoagulation therapy.
  8. Any other patients who are judged by principal Investigator to be inappropriate for participation in the trial.
  9. Existing hemorrhagic disease or coagulation problems creating inability to obtain homeostasis at entry site.
  10. The patient has history of or known reaction or sensitivity to contrast agent and is unable to be premedicated.
  11. Hemodynamic instability at the time of intervention.
  12. Severe chronic renal insufficiency (plasma/ serum creatinine > 2.5mg/dl) at the time of intervention, except for patients on dialysis.
  13. The lesion is 0.0.1. (Medina classification).
  14. The bifurcation lesion involves an anastamosis site from previous a coronary artery bypass surgery.
  15. Acute MI or recent MI with CPK > 3 times the normal value prior to intervention (during index hospitalization).
  16. Other significant lesion in the same vessel.
  17. Other lesion in a different vessel not successfully treated

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Non-blinded IVUS assessment
The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
Blinded IVUS assessment
After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
Only the angiogram is used for stent placement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IVUS with VH guidance leads to better post procedural outcomes when compared
Time Frame: 2 years
The primary objective of this randomized study is to demonstrate that pre-intervention IVUS can provide more accurate information on lesion characteristics than information derived from pre-procedural angiogram alone. This will be determined by full lesion coverage, no acute evidence of plaque protrusion or dissection at the stent edge, no evidence of stent underexpansion, no evidence of stent malapposition, or no significant side branch disease left behind.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Thierry Lefevre, M.D., Institute Hospitalier J Cartier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2008

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

May 14, 2014

First Submitted That Met QC Criteria

December 10, 2014

First Posted (Estimated)

December 15, 2014

Study Record Updates

Last Update Posted (Actual)

June 17, 2024

Last Update Submitted That Met QC Criteria

June 14, 2024

Last Verified

June 1, 2024

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe